Interpretation of anti-inflammatory reliever and maintenance and reliever therapy for children in Global Initiative for Asthma (GINA) 2025 Update
10.3760/cma.j.cn101070-20250807-00598
- VernacularTitle:全球哮喘防治创议(GINA 2025)关于儿童抗炎缓解药物与维持和缓解治疗解读
- Author:
Peng HAN
1
;
Yuejie ZHENG
;
Yanmin BAO
;
Kunling SHEN
Author Information
1. 深圳市儿童医院呼吸科，深圳 518038
- Publication Type:Journal Article
- Keywords:
Asthma;
Global Initiative for Asthma;
Anti-inflammatory reliever;
Maintenance and reliever therapy;
Child
- From:
Chinese Journal of Applied Clinical Pediatrics
2025;40(11):817-820
- CountryChina
- Language:Chinese
-
Abstract:
The Global Initiative for Asthma (GINA) continues to optimize asthma treatment strategies and has introduced the concepts of anti-inflammatory reliever (AIR) and maintenance and reliever therapy(MART). AIR mainly includes Budesonide-Formoterol, Beclomethasone-Formoterol, and inhaled corticosteroids(ICS)combined with short-acting beta2-agonist.MART refers to a treatment regimen that utilizes the same ICS-Formoterol combination for both maintenance and reliever therapy.Currently, AIR and MART are recommended for the treatment of asthma in children aged 6 years and older, adolescents and adults.This article provides an interpretation of the pediatric AIR and MART content in GINA 2025, highlighting their clinical application in pediatric asthma treatment and their role in asthma action plans, with the aim of providing a reference for clinicians to optimize the treatment of pediatric asthma.
